Description
Inspra Coated Tablets 25 mg. №30
Ingredients
Each coated tablet contains 25 mg of eplerenone.
Mechanism of Action
Eplerenone, a selective aldosterone blocker, acts by competitively inhibiting aldosterone binding to its receptors in the distal convoluted tubules and collecting ducts of the kidney. This results in increased excretion of sodium and water while retaining potassium, thus reducing blood pressure and fluid overload in heart failure.
Pharmacological Properties
Eplerenone exhibits high selectivity for aldosterone receptors, leading to minimal interaction with other steroid receptors. It has a moderate half-life allowing for once-daily dosing and is primarily metabolized in the liver.
Indications for Use
Inspra is indicated for the treatment of hypertension to lower blood pressure and for improving survival following a heart attack in patients with heart failure and left ventricular dysfunction.
Contraindications
Do not use Inspra if you have a known hypersensitivity to eplerenone or any component of the formulation. It is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min) and hyperkalemia.
Side Effects
- Common side effects may include hyperkalemia, dizziness, fatigue, and diarrhea.
- Less common but serious side effects include renal impairment, angioedema, and hepatic failure.
Usage Instructions
The recommended dosage of Inspra is one 25 mg tablet taken orally once daily with or without food. It is essential to follow the prescribed regimen strictly.
Benefits Compared to Analogues
Inspra offers the advantage of selective aldosterone blockade with reduced risk of hormonal side effects compared to non-selective mineralocorticoid receptor antagonists.
Suitable Patient Groups
Inspra is suitable for adult patients with hypertension and heart failure. It is not recommended for use in children, as safety and efficacy have not been established in this population. Caution is advised when prescribing to elderly patients due to the risk of hyperkalemia and renal impairment.
Storage and Shelf Life
Store Inspra at room temperature away from moisture and heat. The shelf life of the product is as indicated on the packaging.
Packaging Description
Inspra is available in blister packs containing 30 coated tablets. The packaging should be intact and undamaged before use.
Scientific Evidence
Eplerenone has been extensively studied in clinical trials demonstrating its efficacy in reducing cardiovascular events and mortality in patients with heart failure. Clinical studies have shown that eplerenone, as an aldosterone antagonist, provides additional benefits beyond standard therapy in heart failure management.
Additional Information
Regular monitoring of potassium levels is crucial during Inspra therapy to prevent hyperkalemia. Patients should promptly report any symptoms of hyperkalemia such as muscle weakness, confusion, or irregular heartbeat to their healthcare provider. Prior to initiating Inspra, inform your doctor about all medications, especially potassium supplements or potassium-sparing diuretics, to avoid potential drug interactions.
